검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC) RemeGen Co., Ltd.·Urothelial Carcinoma 51 trials |
|---|---|
Overview Program | RC48-ADC |
Overview Company | RemeGen Co., Ltd. |
Overview Modality | ADC |
Overview Target | Urothelial Carcinoma |
Overview Indication | Salivary Gland Tumors |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis |
MoA Biomarker | HER2-expressing cancers, including those with HER2-low expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).. IntroductionThis study aims to investigate the effectiveness and safety of combining the antibody-drug conjugate (ADC) disitamab vedotin (RC48) with the established PRaG regimen (PD-1 inh… |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC) RemeGen Co., Ltd.·Urothelial Carcinoma 51 trials |
|---|---|
Overview Program | RC48-ADC |
Overview Company | RemeGen Co., Ltd. |
Overview Modality | ADC |
Overview Target | Urothelial Carcinoma |
Overview Indication | Salivary Gland Tumors |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis |
MoA Biomarker | HER2-expressing cancers, including those with HER2-low expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).. IntroductionThis study aims to investigate the effectiveness and safety of combining the antibody-drug conjugate (ADC) disitamab vedotin (RC48) with the established PRaG regimen (PD-1 inh… |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교